Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MetaVia Inc. (MTVA : NSDQ)

• Company Description    MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $1.38 Daily Weekly Monthly 20 Day Moving Average: 61,257 shares Shares Outstanding: 5.16 (millions) Market Capitalization: $7.13 (millions) Beta: 0.96 52 Week High: $14.85 52 Week Low: $0.97 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.34% -14.44% 12 Week -4.17% -6.51% Year To Date -83.61% -85.25%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 545 Concord Avenue Suite 210 - Cambridge,MA 02138 USA ph: 857-702-9600 fax: 734-293-0444 ir@metaviatx.com http://www.metaviatx.com

• General Corporate Information    Officers Hyung Heon Kim - Chief Executive Officer; President and Director Andrew I. Koven - Chairman of the Board Marshall H. Woodworth - Chief Financial Officer Mark A. Glickman - Director Jason L. Groves - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 64132R503 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 5.16 Most Recent Split Date: 12.00 (0.09:1) Beta: 0.96 Market Capitalization: $7.13 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.95 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.79 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.04 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 68.53% vs. Previous Quarter: -13.92% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -209.67 03/31/26 - -172.92 ROA 09/30/26 - - 06/30/26 - -107.91 03/31/26 - -89.39 Current Ratio 09/30/26 - - 06/30/26 - 2.06 03/31/26 - 2.73 Quick Ratio 09/30/26 - - 06/30/26 - 2.06 03/31/26 - 2.73 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 1.32 03/31/26 - 1.76 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©